AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions

by Barry101 | Feb 8, 2024 | Press Release

Efficacy results offer preliminary evidence that Ampligen may reduce fatigue in subjects with Post-COVID conditions Safety results show Ampligen is generally well tolerated in the treatment of Post-COVID Conditions OCALA, Fla., Feb. 08, 2024 — AIM ImmunoTech...

AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer

by Barry101 | Jan 24, 2024 | Press Release

Subject enrollment is expected in Q1 2024OCALA, Fla., Jan. 24, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has received authorization from the Erasmus Medical Center (“Erasmus...

AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer

by Barry101 | Jan 22, 2024 | Press Release

First enrollment takes place at Erasmus Medical Center in Rotterdam, NetherlandsOCALA, Fla., Jan. 22, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the first subject has been enrolled at...

AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

by Barry101 | Jan 10, 2024 | Press Release

First enrollment and first subject dosing expected soon at Erasmus Medical Center in Rotterdam, Netherlands Management discusses the announcement and what this means here: video OCALA, Fla., Jan. 10, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM)...

AIM Shareholders Elect All Four Company Director Nominees at 2023 Annual Meeting

by Barry101 | Jan 5, 2024 | Press Release

OCALA, Fla. – AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that shareholders have elected all four of the Company’s directors, Stewart L. Appelrouth, Nancy K. Bryan, Thomas K. Equels and William...

Delaware Court Rules in Favor of AIM ImmunoTech and Upholds Board’s Determination that Activist Group’s Nominations Are Invalid

by Barry101 | Dec 29, 2023 | Press Release

Court Finds Activist Group “Flouted” AIM’s Bylaws by Failing to Provide Required Information AIM Will Reconvene Annual Meeting Today and then Adjourn Until January 5th Any Proxies Submitted by Activist Group Will Be Disregarded AIM Urges Shareholders...